Ironwood Pharmaceuticals (STU:I76) Total Liabilities : €707.8 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ironwood Pharmaceuticals Total Liabilities?

Ironwood Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €707.8 Mil.

Ironwood Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 (€796.21 Mil) to Dec. 2023 (€749.53 Mil) and declined from Dec. 2023 (€749.53 Mil) to Mar. 2024 (€707.79 Mil).

Ironwood Pharmaceuticals's annual Total Liabilities declined from Dec. 2021 (€461.10 Mil) to Dec. 2022 (€423.05 Mil) but then increased from Dec. 2022 (€423.05 Mil) to Dec. 2023 (€749.53 Mil).

Ironwood Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Ironwood Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals Total Liabilities Chart

Ironwood Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

446.40

408.20

461.10

423.05

749.53

Ironwood Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															418.83	876.85	796.21	749.53	707.79

Ironwood Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ironwood Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	253.185	+	(470.285	+	26.056
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	749.5

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	431.974	-	-317.553
	=	749.5

Ironwood Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	232.247	+	(448.483	+	27.06
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	707.8

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	403.713	-	-304.077
	=	707.8

Ironwood Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ironwood Pharmaceuticals (STU:I76) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (STU:I76) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

IRWD:USA I76:Germany

Address

100 Summer Street, Suite 2300, Boston, MA, USA, 02110

Website

https://www.ironwoodpharma.com

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ironwood Pharmaceuticals (STU:I76) Headlines

No Headlines